News coverage about Eiger Biopharmaceuticals (NASDAQ:EIGR) has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eiger Biopharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.4842424626829 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

Eiger Biopharmaceuticals (NASDAQ EIGR) traded up $0.10 on Wednesday, reaching $9.50. 53,125 shares of the company traded hands, compared to its average volume of 171,697. The company has a market cap of $99.91, a PE ratio of -1.95 and a beta of 1.70. Eiger Biopharmaceuticals has a 1-year low of $6.10 and a 1-year high of $16.20. The company has a quick ratio of 5.78, a current ratio of 5.78 and a debt-to-equity ratio of 1.19.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.09). equities research analysts predict that Eiger Biopharmaceuticals will post -4.34 EPS for the current fiscal year.

EIGR has been the subject of several research analyst reports. ValuEngine raised shares of Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Ladenburg Thalmann Financial Services initiated coverage on shares of Eiger Biopharmaceuticals in a report on Wednesday, January 3rd. They issued a “buy” rating and a $32.00 price target for the company. Zacks Investment Research raised shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a report on Tuesday, January 9th. Piper Jaffray Companies reissued an “overweight” rating and issued a $17.00 price target (down previously from $35.00) on shares of Eiger Biopharmaceuticals in a report on Tuesday, January 16th. Finally, Oppenheimer set a $26.00 price target on shares of Eiger Biopharmaceuticals and gave the company a “buy” rating in a report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. Eiger Biopharmaceuticals has an average rating of “Buy” and an average price target of $27.25.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Eiger Biopharmaceuticals (EIGR) Share Price” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Insider Buying and Selling by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with's FREE daily email newsletter.